Solenne Rudelin

Solenne Rudelin

Associate Director, Market Access

Key Knowledge Areas:

- Market Access
- Economic strategy
- Regulatory Intelligence

Solenne is a pharmacist and completed her Pharmaceutical education at the University of Tours, France (2003). She also obtained a Master Degree in Economic Affairs at the University of Paris V (2003).

 

Solenne has 15 years of experience in economic affairs, especially in the consulting field.

 

She began her career in 2003 at AVENTIS Laboratories as a Regulatory Affairs Officer where she gained practical experience in the Regulatory Affairs field (registration/advertising) and Economic Affairs field (Transparency file) for Oncology and Gynecology products.

 

In 2004, Solenne joined PFIZER Laboratories, as advertising control pharmacist, where she was in charge of the advertising control over a range of products in infectiology and rheumatology and then the Amgen laboratories as Health economist pharmacist. In this capacity, she participated in the writing of transparency file as well as the regulatory intelligence.

At the end of 2004, she moved to consultancy by joining CARRE CASTAN CONSULTANTS and then PAREXEL International as Economic Affairs Consultant. She was in charge of the transparency and economic files and the Regulatory Consulting.

 

After 3 years, Solenne joined A.R.C. Pharma as Economic Affairs Consultant and became Responsible for the Economic Unit. Managing the economic unit, she wrote and coordinated files for French Health Authorities (HAS and CEPS), provided technical and strategic advices on economic affairs, was involved in the regulatory intelligence and gave inter-firm formations relating to market access.

 

Since 2014, she has also been a temporary speaker at the Pharmaceutical Sciences University of Tours, where she still brought her knowledge and experience to students.

 

After 2 years of experience within the pharmaceutical industry and 13 years of experience in the field of economic affairs consulting, she joined BLUE-REG PHARMA CONSULT in September 2018, as Associate Director.

Discover our last white Paper

Learn more